

Regimen Reference Order – THOR – osimertinib

ARIA: LUNG – [osimertinib]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)
Indication for Use: Non-Small Cell Lung Cancer EGFR T790M Mutation-Positive Locally Advanced or Metastatic

Proceed with treatment if:

- **ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$**
- **AST/ALT less than 5 times upper limit of normal**
- **Total bilirubin less than 1.5 times upper limit of normal**
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – THOR - osimertinib

Drug	Dose	CCMB Administration Guideline
osimertinib	80 mg	Orally once daily (with or without food)
osimertinib (Tagrisso®) available dosage strength: 40 mg and 80 mg tablets		
Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

All cycles

- EKG
 - at baseline, then
 - 2 to 4 weeks after starting osimertinib, then
 - every 3 to 4 months as per physician order

Baseline and at every clinic visit (at least every 3 to 4 months)

- CBC, biochemistry as per physician order
- Physical examination, chest x-ray as per physician order
- Clinical toxicity assessment at each visit (skin, gastrointestinal, cardiac, ocular toxicities)

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
loperamide	2 – 4 mg	Orally as directed below

INSTRUCTIONS FOR PATIENT

- Inform patient that any new/worsening cough or shortness of breath must be reported and assessed urgently by the Oncologist/FPO because of risk of pneumonitis
- Patients should be instructed to purchase loperamide at their retail pharmacy
- Patients should take loperamide 4 mg (two 2 mg tablets) if they have loose bowel movement and repeat every 2 hours as needed
 - Patients should not exceed a maximum of 8 tablets in a 24 hour period
 - Patient should contact their cancer team if more than 3 loose bowel movements in a 24 hour period
- Patients should notify clinic prior to starting any new medication. osimertinib has potential for drug-drug interactions
- Avoid grapefruit or grapefruit juice

ADDITIONAL INFORMATION

- QT prolongation has been associated with osimertinib